Proteopedia - User contributions [en]

Sandbox Reserved 1743

2022-11-23T17:41:19Z

Kimberly Lane:

{{Sandbox_Reserved_Kim_Lane}}
==Your Heading Here (maybe something like 'Structure')==
<StructureSection load='1acj' size='340' side='right' caption='Structure 1ACJ' scene='0'>
This is a default text for your page ''''''. Click above on '''edit this page''' to modify. Be careful with the < and > signs.
You may include any references to papers as in: the use of JSmol in Proteopedia <ref>DOI 10.1002/ijch.201300024</ref> or to the article describing Jmol <ref>PMID:21638687</ref> to the rescue.

== Function ==

Beta-glucuronidase <StructureSection load='3lpf' size='340' side='right' caption='Beta-glucuronidase' scene='0'>

== Disease ==

== Relevance ==

== Structural highlights ==

This is a sample scene created with SAT to <scene name="/12/3456/Sample/1">color</scene> by Group, and another to make <scene name="/12/3456/Sample/2">a transparent representation</scene> of the protein. You can make your own scenes on SAT starting from scratch or loading and editing one of these sample scenes.

</StructureSection>
== References ==
<references/>

Sandbox Reserved 1743

2022-11-23T17:40:36Z

Kimberly Lane:

{{Sandbox_Reserved_Kim_Lane}}
==Your Heading Here (maybe something like 'Structure')==
<StructureSection load='1acj' size='340' side='right' caption='Structure 1ACJ' scene=''>
This is a default text for your page ''''''. Click above on '''edit this page''' to modify. Be careful with the < and > signs.
You may include any references to papers as in: the use of JSmol in Proteopedia <ref>DOI 10.1002/ijch.201300024</ref> or to the article describing Jmol <ref>PMID:21638687</ref> to the rescue.

== Function ==

Beta-glucuronidase <StructureSection load='3lpf' size='340' side='right' caption='Beta-glucuronidase' scene=''>

== Disease ==

== Relevance ==

== Structural highlights ==

This is a sample scene created with SAT to <scene name="/12/3456/Sample/1">color</scene> by Group, and another to make <scene name="/12/3456/Sample/2">a transparent representation</scene> of the protein. You can make your own scenes on SAT starting from scratch or loading and editing one of these sample scenes.

</StructureSection>
== References ==
<references/>

User:Kimberly Lane/Sandbox 1

2019-04-12T19:52:22Z

Kimberly Lane:

==Your Heading Here (maybe something like 'Structure')==
<StructureSection load='3lpf' size='340' side='right' caption='Caption for this structure' scene=''>
This is a default text for your page '''Kimberly Lane/Sandbox 1'''. Click above on '''edit this page''' to modify. Be careful with the < and > signs.
You may include any references to papers as in: the use of JSmol in Proteopedia <ref>DOI 10.1002/ijch.201300024</ref> or to the article describing Jmol <ref>PMID:21638687</ref> to the rescue.

== Function ==

== Disease ==

== Relevance ==

== Structural highlights ==

This is a sample scene created with SAT to <scene name="/12/3456/Sample/1">color</scene> by Group, and another to make <scene name="/12/3456/Sample/2">a transparent representation</scene> of the protein. You can make your own scenes on SAT starting from scratch or loading and editing one of these sample scenes.

</StructureSection>
== References ==
<references/>

User:Kimberly Lane/Sandbox 1

2019-02-01T04:02:18Z

Kimberly Lane: New page: ==Your Heading Here (maybe something like 'Structure')== <StructureSection load='1stp' size='340' side='right' caption='Caption for this structure' scene=''> This is a default text for you...

==Your Heading Here (maybe something like 'Structure')==
<StructureSection load='1stp' size='340' side='right' caption='Caption for this structure' scene=''>
This is a default text for your page '''Kimberly Lane/Sandbox 1'''. Click above on '''edit this page''' to modify. Be careful with the < and > signs.
You may include any references to papers as in: the use of JSmol in Proteopedia <ref>DOI 10.1002/ijch.201300024</ref> or to the article describing Jmol <ref>PMID:21638687</ref> to the rescue.

== Function ==

== Disease ==

== Relevance ==

== Structural highlights ==

This is a sample scene created with SAT to <scene name="/12/3456/Sample/1">color</scene> by Group, and another to make <scene name="/12/3456/Sample/2">a transparent representation</scene> of the protein. You can make your own scenes on SAT starting from scratch or loading and editing one of these sample scenes.

</StructureSection>
== References ==
<references/>

User:Kimberly Lane

2019-02-01T04:00:38Z

Kimberly Lane:

* Full Real Name: Kimberly Lane

* Position: Associate Professor

* Institution (NO ABBREVIATIONS): Radford University

* City, State/Province, Country: Radford, VA, USA

* Field of Expertise or Study: Ph.D. in Biochemistry

*[[User:Kimberly Lane/Sandbox 1]]

User:Kimberly Lane

2019-02-01T02:23:58Z

Kimberly Lane:

Glucuronidase

2014-08-06T16:08:02Z

Kimberly Lane:

==β-Glucuronidase==
<StructureSection load='3hn3' size='340' side='right' caption='Ribbon diagram of human β-glucuronidase' scene=''>

This tutorial illustrates the quaternary structures of the human and ''E. coli'' β-glucuronidase enzyme.

== Function ==
β-glucuronidase is a ubiquitous enzyme that catalyzes the hydrolysis of a glucuronide moiety from a variety of substrates. This enzyme is present throughout biological systems, including bacteria up through humans.

== Relevance ==
Deficiencies in the human form of β-glucuronidase (<scene name='59/596447/Human_bglucuronidase/1'>overall structure</scene>, PDB ID 3HN3<ref>DOI:10.2210/pdb3hn3/pdb</ref>) is associated with a disease known as Sly Syndrome (AKA Mucopolysaccharidosis VII -- MPS VII). This disease is characterized by mental retardation, short stature, macrocephaly, and enlarged joints. As is commonly seen with genetic disorders, patients with this disease present a spectrum of symptom severity, but the disease is always ultimately fatal.

The ''E. coli'' form of β-glucuronidase (<scene name='59/596447/E_coli_b-glucuronidase/1'>overall structure</scene>, PDB ID 3LPF<ref>DOI:10.2210/pdb3lpf/pdb</ref>) is associated with the side effects seen with administration of the cancer chemotherapy drug CPT-11. This drug gets converted to SN38, a topoisomerase inhibitor, by the liver. The body adds a glucuronide group to this molecule (now SN38-G) to mark it for elimination, which partially occurs through the intestine. Once in the intestine, bacterial β-glucuronidase cleaves the glucuronide from the SN38-G, releasing the SN38 into the intestinal lumen. The released SN38 prevents cell division, compromising the epithelial lining of the intestines, a painful and dangerous side-effect of CPT-11 administration.

Selective inhibition of bacterial β-glucuronidase is desired to alleviate this side-effect of CPT-11 treatment, hopefully without inhibiting the human form of the enzyme.

== Structural highlights ==
The structure of ''E. coli'' β-glucuronidase contains 4 identical subunits (<scene name='59/596447/E_coli_b-glucuronidase/1'>homotetramer</scene>).

The structure of the enzyme contains both α-helix (blue) and β-sheet (yellow) forms of <scene name='59/596447/E_coli_b-glucuronidase3/1'>secondary structure</scene>, with the β-sheets arranged in β-barrels in an immunoglobulin-like fold.

</StructureSection>
== References ==
<ref>DOI:10.2210/pdb3hn3/pdb</ref>
<ref>DOI:10.2210/pdb3lpf/pdb</ref>

Glucuronidase

2014-08-06T16:06:06Z

Kimberly Lane:

==β-Glucuronidase==
<StructureSection load='3hn3' size='340' side='right' caption='Ribbon diagram of human β-glucuronidase' scene=''>

This tutorial illustrates the quaternary structures of the human and ''E. coli'' β-glucuronidase enzyme.

== Function ==
β-glucuronidase is a ubiquitous enzyme that catalyzes the hydrolysis of a glucuronide moiety from a variety of substrates. This enzyme is present throughout biological systems, including bacteria up through humans.

== Relevance ==
Deficiencies in the human form of β-glucuronidase (<scene name='59/596447/Human_bglucuronidase/1'>overall structure</scene>, PDB ID 3HN3) is associated with a disease known as Sly Syndrome (AKA Mucopolysaccharidosis VII -- MPS VII). This disease is characterized by mental retardation, short stature, macrocephaly, and enlarged joints. As is commonly seen with genetic disorders, patients with this disease present a spectrum of symptom severity, but the disease is always ultimately fatal.

The ''E. coli'' form of β-glucuronidase (<scene name='59/596447/E_coli_b-glucuronidase/1'>overall structure</scene>, PDB ID 3LPF) is associated with the side effects seen with administration of the cancer chemotherapy drug CPT-11. This drug gets converted to SN38, a topoisomerase inhibitor, by the liver. The body adds a glucuronide group to this molecule (now SN38-G) to mark it for elimination, which partially occurs through the intestine. Once in the intestine, bacterial β-glucuronidase cleaves the glucuronide from the SN38-G, releasing the SN38 into the intestinal lumen. The released SN38 prevents cell division, compromising the epithelial lining of the intestines, a painful and dangerous side-effect of CPT-11 administration.

Selective inhibition of bacterial β-glucuronidase is desired to alleviate this side-effect of CPT-11 treatment, hopefully without inhibiting the human form of the enzyme.

== Structural highlights ==
The structure of ''E. coli'' β-glucuronidase contains 4 identical subunits (<scene name='59/596447/E_coli_b-glucuronidase/1'>homotetramer</scene>).

The structure of the enzyme contains both α-helix (blue) and β-sheet (yellow) forms of <scene name='59/596447/E_coli_b-glucuronidase3/1'>secondary structure</scene>, with the β-sheets arranged in β-barrels in an immunoglobulin-like fold.

</StructureSection>
== References ==
<ref>DOI:10.2210/pdb3hn3/pdb</ref>

Glucuronidase

2014-08-06T15:59:39Z

Kimberly Lane:

==β-Glucuronidase==
<StructureSection load='3hn3' size='340' side='right' caption='Ribbon diagram of human β-glucuronidase' scene=''>

This tutorial illustrates the quaternary structures of the human and ''E. coli'' β-glucuronidase enzyme.

== Function ==
β-glucuronidase is a ubiquitous enzyme that catalyzes the hydrolysis of a glucuronide moiety from a variety of substrates. This enzyme is present throughout biological systems, including bacteria up through humans.

== Relevance ==
Deficiencies in the human form of β-glucuronidase (<scene name='59/596447/Human_bglucuronidase/1'>overall structure</scene>, PDB ID 3HN3) is associated with a disease known as Sly Syndrome (AKA Mucopolysaccharidosis VII -- MPS VII). This disease is characterized by mental retardation, short stature, macrocephaly, and enlarged joints. As is commonly seen with genetic disorders, patients with this disease present a spectrum of symptom severity, but the disease is always ultimately fatal.

The ''E. coli'' form of β-glucuronidase (<scene name='59/596447/E_coli_b-glucuronidase/1'>overall structure</scene>, PDB ID 3LPF) is associated with the side effects seen with administration of the cancer chemotherapy drug CPT-11. This drug gets converted to SN38, a topoisomerase inhibitor, by the liver. The body adds a glucuronide group to this molecule (now SN38-G) to mark it for elimination, which partially occurs through the intestine. Once in the intestine, bacterial β-glucuronidase cleaves the glucuronide from the SN38-G, releasing the SN38 into the intestinal lumen. The released SN38 prevents cell division, compromising the epithelial lining of the intestines, a painful and dangerous side-effect of CPT-11 administration.

Selective inhibition of bacterial β-glucuronidase is desired to alleviate this side-effect of CPT-11 treatment, hopefully without inhibiting the human form of the enzyme.

== Structural highlights ==
The structure of ''E. coli'' β-glucuronidase contains 4 identical subunits (<scene name='59/596447/E_coli_b-glucuronidase/1'>homotetramer</scene>).

The structure of the enzyme contains both α-helix (blue) and β-sheet (yellow) forms of <scene name='59/596447/E_coli_b-glucuronidase3/1'>secondary structure</scene>, with the β-sheets arranged in β-barrels in an immunoglobulin-like fold.

</StructureSection>
== References ==
<references/>

Glucuronidase

2014-08-06T15:53:16Z

Kimberly Lane: New page: ==β-Glucuronidase== <StructureSection load='3hn3' size='340' side='right' caption='Ribbon diagram of human β-glucuronidase' scene=''> This tutorial illustrates the quaternary st...

==β-Glucuronidase==
<StructureSection load='3hn3' size='340' side='right' caption='Ribbon diagram of human β-glucuronidase' scene=''>

This tutorial illustrates the quaternary structures of the human and ''E. coli'' β-glucuronidase enzyme.

== Function ==
β-glucuronidase is a ubiquitous enzyme that catalyzes the hydrolysis of a glucuronide moiety from a variety of substrates. This enzyme is present throughout biological systems, including bacteria up through humans.

== Relevance ==
Deficiencies in the human form of β-glucuronidase (<scene name='59/596447/Human_bglucuronidase/1'>overall structure</scene>) is associated with a disease known as Sly Syndrome (AKA Mucopolysaccharidosis VII -- MPS VII). This disease is characterized by mental retardation, short stature, macrocephaly, and enlarged joints. As is commonly seen with genetic disorders, patients with this disease present a spectrum of symptom severity, but the disease is always ultimately fatal.

The ''E. coli'' form of β-glucuronidase (<scene name='59/596447/E_coli_b-glucuronidase/1'>overall structure</scene>) is associated with the side effects seen with administration of the cancer chemotherapy drug CPT-11. This drug gets converted to SN38, a topoisomerase inhibitor, by the liver. The body adds a glucuronide group to this molecule (now SN38-G) to mark it for elimination, which partially occurs through the intestine. Once in the intestine, bacterial β-glucuronidase cleaves the glucuronide from the SN38-G, releasing the SN38 into the intestinal lumen. The released SN38 prevents cell division, compromising the epithelial lining of the intestines, a painful and dangerous side-effect of CPT-11 administration.

Selective inhibition of bacterial β-glucuronidase is desired to alleviate this side-effect of CPT-11 treatment, hopefully without inhibiting the human form of the enzyme.

== Structural highlights ==
The structure of ''E. coli'' β-glucuronidase contains 4 identical subunits (<scene name='59/596447/E_coli_b-glucuronidase/1'>homotetramer</scene>).

The structure of the enzyme contains both α-helix (blue) and β-sheet (yellow) forms of <scene name='59/596447/E_coli_b-glucuronidase3/1'>secondary structure</scene>, with the β-sheets arranged in β-barrels in an immunoglobulin-like fold.

</StructureSection>
== References ==
<references/>